Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:45 AM
Ignite Modification Date:
2025-12-25 @ 12:45 AM
NCT ID:
NCT00003567
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* One of the following histologically confirmed diseases for which no curative surgical, radiotherapy, or chemotherapy programs are available and standard therapy offers, at best, a modest clinical benefit
* Solid tumors
* Gliomas
* Non-Hodgkin's lymphoma
* Primary and metastatic CNS malignancies are eligible
* Evaluable or measurable disease
* CD34 count at least 2.0 cells/μL
* No bone marrow involvement
* Histologically negative bone marrow biopsy
PATIENT CHARACTERISTICS:
Age:
* 18 to 70
Performance status:
* ECOG 0-2
Life expectancy:
* At least 12 weeks
Hematopoietic:
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* Hemoglobin at least 8.5 g/dL
Hepatic:
* Bilirubin no greater than 1.5 mg/dL
* AST and ALT less than 2.5 times normal
* Prothrombin time less than 1.2 times normal
Renal:
* Creatinine no greater than 2.0 mg/dL
Cardiovascular:
* No acute cardiac disease by EKG
Pulmonary:
* No symptomatic pulmonary disease
Other:
* HIV negative
* No other severe comorbid conditions
* Not pregnant or nursing
* Fertile patients must use effective contraception during and for 2 months after study completion
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* See Chemotherapy
* No prior hematopoietic stem cell transplantation
Chemotherapy:
* No prior high-dose chemotherapy
* Prior adjuvant chemotherapy allowed
Endocrine therapy:
* Not specified
Radiotherapy:
* No prior radiotherapy to 25% or more of bone marrow
Surgery:
* Not specified
Other:
* At least 4 weeks since prior myelosuppressive therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT00003567
Study Brief:
Protocol Section:
NCT00003567